Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: Occurrences, reasons, and long-term clinical outcomes

Clinical Cardiology
Xin-Yun LiChun-Jie Fan

Abstract

Although switching between ticagrelor and clopidogrel is common in clinical practice, the efficacy and safety of this de-escalation remain controversial. We assessed the occurrences, reasons, and outcomes of switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing successful primary percutaneous coronary intervention (PCI). A total of 653 patients with STEMI were randomly assigned to receive loading dose of ticagrelor or clopidogrel before PCI and then received maintenance dose, respectively, for 12 months follow-up. The primary outcome was major adverse cardiac events (MACE), including cardiovascular death, nonfatal myocardial infarction, and stroke. The secondary outcome included unexpected rehospitalization for angina, coronary revascularization, and stent thrombosis. The safety outcome was bleeding described by the Bleeding Academic Research Consortium (BARC) criteria. A total of 602 participants completed the study. The rate of switching from ticagrelor to clopidogrel was 48.6% and the main reason was financial burden. The rate of secondary ischemic events in the de-escalation group was higher than that in the ticagrelor group (15.1% vs 5.6%, P = 0.008), but lo...Continue Reading

References

Oct 24, 2007·Circulation·Kristian ThygesenNawwar Al-Attar
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Oct 8, 2014·Nature Reviews. Cardiology·Francesco Franchi, Dominick J Angiolillo
Aug 19, 2015·Nature Reviews. Cardiology·Fabiana RolliniDominick J Angiolillo
Dec 23, 2016·Thrombosis and Haemostasis·Francesco Franchi, Fabiana Rollini
Apr 5, 2017·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Leonardo De LucaLeonardo Bolognese
May 24, 2017·European Heart Journal Supplements : Journal of the European Society of Cardiology·Xuyun WangYundai Chen
Nov 1, 2017·Circulation·Dominick J AngiolilloMatthew J Price

❮ Previous
Next ❯

Citations

Mar 7, 2020·JACC. Cardiovascular Interventions·Dominick J AngiolilloMatthew J Price

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.